Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors

NCT03114319 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03114319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03114319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
May 26, 2017
Completion date
July 4, 2025
Enrollment
227 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced egfr mutant non small cell lungcancer (nsclc), advanced gastrointestinal stromal tumors (gist), advanced nras/braft wt cutaneous melanoma, esophageal squamous cell cancer (scc), head/neck scc, kras g12-mutant nsclc, melanoma